Dr Jo Kate Perry
PhD, BSc (Hons)
Dr Perry is a cell and molecular biologist with expertise in endocrinology and oncology. Her research interests lie in the involvement of growth factors and hormones in human development and disease including complications of pregnancy and cancer.
Dr Perry completed her PhD at the Institute of Cancer Research in London and was awarded a National Health and Medical Research Council (NHMRC) Peter Doherty Postdoctoral Fellowship to work at the Murdoch Childrens Research Institute in Melbourne. She joined the Liggins Institute in 2005.
Research | Current
- The role of placental growth hormone in the development and function of the placenta.
- The contribution of human growth hormone to cancer progression and the mechanistic interactions of this hormone with conventional cancer therapies used clinically.
- Developing small molecule targeted therapies directed against the human growth hormone receptor.
Other research and teaching interests
- Liggins Education Network for Science (LENScience)
Teaching | Current
MEDSCI 302; PHARM 411
- Auckland Cancer Research Network
Selected publications and creative works (Research Outputs)
- Jain, L., Fadason, T., Schierding, W., Vickers, M. H., O'Sullivan JM, & Perry, J. K. (2020). 3D interactions with the growth hormone locus in cellular signalling and cancer-related pathways. Journal of molecular endocrinology, 64 (4), 209-222. 10.1530/jme-20-0010
Other University of Auckland co-authors: Justin O'Sullivan, William Schierding, Mark Vickers
- Lu, M., Flanagan, J. U., Langley, R. J., Hay, M. P., & Perry, J. K. (2019). Targeting growth hormone function: strategies and therapeutic applications. Signal transduction and targeted therapy, 410.1038/s41392-019-0036-y
Other University of Auckland co-authors: Michael Hay, Ries Langley, Jack Flanagan
- Jacobson, E. C., Perry, J. K., Long, D. S., Olins, A. L., Olins, D. E., Wright, B. E., ... O'Sullivan JM (2018). Migration through a small pore disrupts inactive chromatin organization in neutrophil-like cells. BMC Biology, 16 (1)10.1186/s12915-018-0608-2
Other University of Auckland co-authors: Mark Vickers, Justin O'Sullivan
- Liao, S., Vickers, M. H., Stanley, J. L., Baker, P. N., & Perry, J. K. (2018). Human Placental Growth Hormone Variant in Pathological Pregnancies. Endocrinology, 159 (5), 2186-2198. 10.1210/en.2018-00037
Other University of Auckland co-authors: Mark Vickers
- Perry, J. K., Wu, Z.-S., Mertani, H. C., Zhu, T., & Lobie, P. E. (2017). Tumour-derived human growth hormone as a therapeutic target in oncology. Trends in Endocrinology & Metabolism, 28 (8), 587-596. 10.1016/j.tem.2017.05.003
- Liao, S., Vickers, M. H., Taylor, R. S., Fraser, M., McCowan, L. M., Baker, P. N., & Perry, J. K. (2017). Maternal serum placental growth hormone, insulin-like growth factors and their binding proteins at 20 weeks' gestation in pregnancies complicated by gestational diabetes mellitus. Hormones, 16 (3), 282-290. 10.14310/horm.2002.1747
Other University of Auckland co-authors: Mark Vickers, Rennae Taylor, Mhoyra Fraser, Lesley McCowan
- Evans, A., Jamieson, S. M. F., Liu, D. X., Wilson, W. R., & Perry, J. K. (2016). Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model. Cancer Letters, 379 (1), 117-123. 10.1016/j.canlet.2016.05.031
Other University of Auckland co-authors: Stephen Jamieson
- Vouyovitch, C. M., Perry, J. K., Liu, D. X., Bezin, L., Vilain, E., Diaz, J. J., ... Mertani, H. C. (2016). WNT4 mediates the autocrine effects of growth hormone in mammary carcinoma cells. Endocrine-Related Cancer, 23 (7), 571-585. 10.1530/ERC-15-0528